Finanzen von PDS Biotechnology Corp (PDSB)PDSBPDS Biotechnology Corp

Evaluating the bottom line, PDS Biotechnology Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -543.97%, provide a clear picture of how effectively PDSB converts its operational activities into shareholder value.

In the context of the broader market, PDSB competes directly with industry leaders such as IMRN and KPRX. With a market capitalization of $12.91M, it holds a leading position in the sector. When comparing efficiency, PDSB's gross margin of N/A stands against IMRN's 63.42% and KPRX's N/A. Such benchmarking helps identify whether PDS Biotechnology Corp is trading at a premium or discount relative to its financial performance.

PDS Biotechnology has been reporting consistent net losses, with a net income of -$7,349,056 for Q1 2026 and a negative EPS of -0.13. The company's total equity has turned negative at -$3,579,739 in Q2 2026, indicating serious financial distress.